Q3 2022 Results slide image

Q3 2022 Results

Company overview Financial performance Cardiovascular Financial review 2022 priorities Innovation: Pipeline overview Immunology Neuroscience Ophthalmology Global Health Other Appendix References Innovation: Clinical trials Abbreviations Oncology Other Biosimilars 82 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation